HRP20110044T2 - Supstituirani glicinamidi s antitrombotičkim i faktor-xa inhibirajućim djelovanjem - Google Patents

Supstituirani glicinamidi s antitrombotičkim i faktor-xa inhibirajućim djelovanjem Download PDF

Info

Publication number
HRP20110044T2
HRP20110044T2 HR20110044T HRP20110044T HRP20110044T2 HR P20110044 T2 HRP20110044 T2 HR P20110044T2 HR 20110044 T HR20110044 T HR 20110044T HR P20110044 T HRP20110044 T HR P20110044T HR P20110044 T2 HRP20110044 T2 HR P20110044T2
Authority
HR
Croatia
Prior art keywords
alkyl
group
groups
methyl
substituted
Prior art date
Application number
HR20110044T
Other languages
English (en)
Croatian (hr)
Inventor
Wienen Wolfgang
Pfau Roland
Gerlach Kai
Dahmann Georg
Priepke Henning
Nar Herbert
Handschuh Sandra
Schuler-Metz Annette
Original Assignee
Boehringer Ingelheim International Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Boehringer Ingelheim International Gmbh filed Critical Boehringer Ingelheim International Gmbh
Publication of HRP20110044T1 publication Critical patent/HRP20110044T1/xx
Publication of HRP20110044T2 publication Critical patent/HRP20110044T2/hr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/08—Bridged systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Rheumatology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Cardiology (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Communicable Diseases (AREA)
  • Vascular Medicine (AREA)
  • Psychiatry (AREA)
  • Psychology (AREA)
  • Pain & Pain Management (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Hospice & Palliative Care (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Dermatology (AREA)
  • Diabetes (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
HR20110044T 2005-06-30 2006-06-28 Supstituirani glicinamidi s antitrombotičkim i faktor-xa inhibirajućim djelovanjem HRP20110044T2 (hr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP05014270 2005-06-30
PCT/EP2006/063611 WO2007003536A1 (de) 2005-06-30 2006-06-28 Substituierte glycinamide mit antithrombotischer und faktor xa-inhibierender wirkung

Publications (2)

Publication Number Publication Date
HRP20110044T1 HRP20110044T1 (hr) 2011-02-28
HRP20110044T2 true HRP20110044T2 (hr) 2012-02-29

Family

ID=35907001

Family Applications (1)

Application Number Title Priority Date Filing Date
HR20110044T HRP20110044T2 (hr) 2005-06-30 2006-06-28 Supstituirani glicinamidi s antitrombotičkim i faktor-xa inhibirajućim djelovanjem

Country Status (32)

Country Link
US (3) US20100216769A1 (sr)
EP (1) EP1899330B9 (sr)
JP (1) JP4768016B2 (sr)
KR (1) KR101321722B1 (sr)
CN (1) CN101213195B (sr)
AR (1) AR054627A1 (sr)
AT (1) ATE489381T1 (sr)
AU (1) AU2006265216B2 (sr)
BR (1) BRPI0612580A8 (sr)
CA (1) CA2613059C (sr)
CY (1) CY1111627T1 (sr)
DE (1) DE502006008392D1 (sr)
DK (1) DK1899330T3 (sr)
EA (1) EA015188B1 (sr)
EC (1) ECSP078058A (sr)
ES (1) ES2357029T3 (sr)
HR (1) HRP20110044T2 (sr)
IL (1) IL188323A (sr)
MX (1) MX2007016253A (sr)
MY (1) MY145883A (sr)
NO (1) NO340670B1 (sr)
NZ (1) NZ565440A (sr)
PE (1) PE20070171A1 (sr)
PL (1) PL1899330T3 (sr)
PT (1) PT1899330E (sr)
RS (1) RS51572B (sr)
SG (1) SG163540A1 (sr)
SI (1) SI1899330T1 (sr)
TW (1) TWI392495B (sr)
UA (1) UA94910C2 (sr)
WO (1) WO2007003536A1 (sr)
ZA (1) ZA200708525B (sr)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101068815B (zh) 2004-10-04 2012-09-05 千禧药品公司 有效作为蛋白激酶抑制剂的内酰胺化合物
PE20080145A1 (es) 2006-03-21 2008-02-11 Janssen Pharmaceutica Nv Tetrahidro-pirimidoazepinas como moduladores de trpv1
WO2008009125A1 (en) * 2006-07-20 2008-01-24 Cascade Therapeutics Inc. Tetrahydro-5h-pyrido[2,3-d]azepines as 5-ht2c ligands
PE20081834A1 (es) * 2006-12-31 2009-01-16 Boehringer Ingelheim Int Proceso para la sintesis de derivados de acido 3-amino-tetrahidrofuran-3-carboxilico y uso de los mismos como medicamentos
EP1975165A1 (de) 2007-03-27 2008-10-01 Boehringer Ingelheim Pharma GmbH & Co. KG Substituierte Pyrrolidinamide, deren Herstellung und deren Verwendung als Arzneimittel
WO2009063028A2 (en) 2007-11-15 2009-05-22 Boehringer Ingelheim International Gmbh Substituted amides, manufacturing and use thereof as medicaments
PE20091102A1 (es) 2007-12-17 2009-07-25 Janssen Pharmaceutica Nv Moduladores imidazolo-, oxazolo-, y tiazolopirimidina del trpv1
JP5684719B2 (ja) 2008-12-05 2015-03-18 ミレニアム ファーマシューティカルズ， インコーポレイテッドＭｉｌｌｅｎｎｉｕｍ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． Ｐｌｋ阻害剤としての５，７−ジヒドロ−６ｈ−ピリミド［５、−４ｄ］［１］ベンゾアゼピン−６−チオン
EP2398781A1 (en) * 2009-02-17 2011-12-28 Msd K.K. 1,4-benzodiazepin-2-on derivatives
WO2011123495A1 (en) 2010-03-30 2011-10-06 Mount Sinai School Of Medicine Influenza virus vaccines and uses thereof
ES2953393T3 (es) 2011-09-20 2023-11-10 Icahn School Med Mount Sinai Vacunas contra el virus de la influenza y sus usos
SG11201504728RA (en) 2012-12-18 2015-07-30 Icahn School Med Mount Sinai Influenza virus vaccines and uses thereof
CN108892661B (zh) * 2014-02-07 2023-03-14 艾克赛特赫拉制药有限责任公司 治疗化合物和组合物
CN105622511B (zh) * 2014-11-03 2018-01-23 北京瑞都医药科技有限公司 一种减肥药物及其制备方法
EP3078378B1 (en) 2015-04-08 2020-06-24 Vaiomer Use of factor xa inhibitors for regulating glycemia
CA3105410A1 (en) 2018-07-05 2020-01-09 Bayer Aktiengesellschaft Substituted thiophenecarboxamides and analogues as antibacterials agents
CN111196772B (zh) * 2018-11-16 2022-09-30 沈阳化工研究院有限公司 一种芳酰氨基异丁酰衍生物及其应用
PL4077317T3 (pl) 2019-12-20 2024-11-04 Bayer Aktiengesellschaft Tienylooksazolony i analogi
JP7502564B2 (ja) 2020-11-06 2024-06-18 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング ２－［（チオフェン－２－イル）ホルムアミド］－ｎ－（フェニル）－２－メチルプロパンアミド誘導体及びその医薬としての使用
WO2025019631A1 (en) 2023-07-19 2025-01-23 Icahn School Of Medicine At Mount Sinai Immunogenic compositions containing inactivated influenza a virus and cpg oligonucleotide adjuvant and uses thereof

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2375920A1 (en) * 1999-06-14 2000-12-21 Eli Lilly And Company Compounds
DE19962924A1 (de) 1999-12-24 2001-07-05 Bayer Ag Substituierte Oxazolidinone und ihre Verwendung
IL150964A0 (en) 2000-03-21 2003-02-12 Smithkline Beecham Corp Protease inhibitors
DE10063008A1 (de) 2000-12-16 2002-06-20 Merck Patent Gmbh Carbonsäureamidderivate
US20040157828A1 (en) 2001-05-17 2004-08-12 Ren Xie Protease inhibitors
JP2004300133A (ja) * 2002-11-19 2004-10-28 Takeda Chem Ind Ltd アミン誘導体
PE20040837A1 (es) 2002-11-19 2004-12-24 Takeda Chemical Industries Ltd Compuestos de amina
DE10254336A1 (de) 2002-11-21 2004-06-03 Merck Patent Gmbh Carbonsäureamide
US7250415B2 (en) * 2003-06-04 2007-07-31 Bristol-Myers Squibb Company 1,1-Disubstitutedcycloalkyl-, glycinamidyl-, sulfonyl-amidino-, and tetrahydropyrimidinyl-containing diaminoalkyl, β-aminoacids, α-aminoacids and derivatives thereof as factor Xa inhibitors
KR20070012552A (ko) 2004-05-13 2007-01-25 베링거 인겔하임 인터내셔날 게엠베하 신규한 치환된 티오펜카복스아미드, 이의 제조방법 및약제로서의 이의 용도
EP1748996A1 (de) * 2004-05-13 2007-02-07 Boehringer Ingelheim International GmbH Substituierte thiophencarbonsäureamide, deren herstellung und deren verwendung als arzneimittel
WO2005111013A1 (de) 2004-05-13 2005-11-24 Boehringer Ingelheim International Gmbh Substituierte thiophen-2-carbonsäureamide, deren herstellung und deren verwendung als arzneimittel
DE102004047840A1 (de) 2004-09-29 2006-03-30 Boehringer Ingelheim Pharma Gmbh & Co. Kg Neue substituierte Thiophencarbonsäureamide, deren Herstellung und deren Verwendung als Arzneimittel
PE20081834A1 (es) 2006-12-31 2009-01-16 Boehringer Ingelheim Int Proceso para la sintesis de derivados de acido 3-amino-tetrahidrofuran-3-carboxilico y uso de los mismos como medicamentos

Also Published As

Publication number Publication date
SG163540A1 (en) 2010-08-30
JP2008546741A (ja) 2008-12-25
BRPI0612580A8 (pt) 2017-12-26
ECSP078058A (es) 2008-01-23
KR20080033318A (ko) 2008-04-16
ZA200708525B (en) 2009-08-26
CN101213195B (zh) 2012-05-09
MX2007016253A (es) 2008-03-07
PT1899330E (pt) 2011-01-11
US20150252050A1 (en) 2015-09-10
JP4768016B2 (ja) 2011-09-07
BRPI0612580A2 (pt) 2010-11-23
HK1116190A1 (en) 2008-12-19
DK1899330T3 (da) 2011-02-21
AR054627A1 (es) 2007-07-04
US20100216769A1 (en) 2010-08-26
US9062034B2 (en) 2015-06-23
CY1111627T1 (el) 2015-10-07
DE502006008392D1 (de) 2011-01-05
UA94910C2 (ru) 2011-06-25
EA200702620A1 (ru) 2008-06-30
PL1899330T3 (pl) 2011-05-31
IL188323A (en) 2013-08-29
EP1899330B1 (de) 2010-11-24
TW200738692A (en) 2007-10-16
EA015188B1 (ru) 2011-06-30
RS51572B (sr) 2011-08-31
NO340670B1 (no) 2017-05-29
PE20070171A1 (es) 2007-03-08
IL188323A0 (en) 2008-04-13
AU2006265216A1 (en) 2007-01-11
CA2613059A1 (en) 2007-01-11
EP1899330B9 (de) 2011-11-09
AU2006265216B2 (en) 2011-09-29
NZ565440A (en) 2011-04-29
WO2007003536A1 (de) 2007-01-11
NO20075186L (no) 2008-02-14
CN101213195A (zh) 2008-07-02
ATE489381T1 (de) 2010-12-15
US9676781B2 (en) 2017-06-13
ES2357029T3 (es) 2011-04-15
TWI392495B (zh) 2013-04-11
CA2613059C (en) 2013-12-24
MY145883A (en) 2012-05-15
KR101321722B1 (ko) 2013-10-25
HRP20110044T1 (hr) 2011-02-28
SI1899330T1 (sl) 2011-03-31
US20130184256A1 (en) 2013-07-18
EP1899330A1 (de) 2008-03-19

Similar Documents

Publication Publication Date Title
HRP20110044T2 (hr) Supstituirani glicinamidi s antitrombotičkim i faktor-xa inhibirajućim djelovanjem
JP2010522713A5 (sr)
ES2677480T3 (es) Agentes que inducen apoptosis
JP2009537483A5 (sr)
PE20060374A1 (es) Inhibidores de cinasa heterociclicos fusionados
RU2552533C2 (ru) Противовирусные соединения и их применения
ES2865182T3 (es) Inhibidor de URAT1
KR20090010098A (ko) Ｘａ 인자 저해제
PE20090288A1 (es) Derivados de quinoxalina como inhibidores de la pi3 quinasa
KR20120107991A (ko) Ｃ형 간염 바이러스 억제제
KR20150118148A (ko) Trk 저해 화합물
ES2558608T3 (es) Derivados hetero-bicíclicos como inhibidores del VHC
RU2011147233A (ru) Азетидинилдиамиды в качестве ингибиторов моноацилглицерин-липазы
HRP20220314T1 (hr) Spojevi n-((het)arilmetil)-heteroaril-karboksamida kao plazma kallikrein inhibitori
KR20110134497A (ko) Ｃ형 간염 바이러스 억제제
RU2014120373A (ru) Соединения азетидина, композиции и их применение в качестве ингибиторов растворимой эпоксидгидролазы
WO2010111673A1 (en) Substituted bicyclic hcv inhibitors
EA026126B1 (ru) Имидазотриазины и имидазопиримидины в качестве ингибиторов киназы
AR072900A1 (es) Agentes terapeuticos derivados de pirazolo[3,4-d]pirimidina
AU2013225173A1 (en) 6 - alkynyl pyridines as SMAC mimetics
JP2010504286A5 (sr)
AR070797A1 (es) Derivados de quinoxalinona como estimulantes de la secrecion de insulina, metodos para obtenerlos y su uso en el tratamiento de la diabetes
PE20060609A1 (es) Derivados de quinuclidinas como antagonistas del receptor muscarinico (m3)
RU2008112691A (ru) Азотсодержащее гетероциклическое соединение и его фармацевтическое применение
KR20140041609A (ko) 선택적 프로테인 키나제 저해제로서 옥사졸 및 티아졸 유도체